Pathologic Function

EMA Identifies Very Rare Eye Condition as Side Effect of Semaglutide

2 days ago talkbio0Tagged Adverse effects, Blindness, Infrequent, Multiple Acyl Coenzyme A Dehydrogenase Deficiency, NAION, Ozempic, Rybelsus, semaglutide, Wegovy

EMA; semaglutide; rare side effect; NAION; vision loss; Ozempic; Wegovy; Rybelsus

AstraZeneca Details Its Oral SERD ‘Switching’ Regimen Amid Feasibility Questions

1 week ago talkbio0Tagged AstraZeneca, camizestrant, CDK4/6 inhibitor, Disease Progression, ESR1 gene, Malignant neoplasm of breast, Mutation, Oral SERD, SERENA-6 trial, treatment resistance

AstraZeneca; oral SERD; camizestrant; breast cancer; ESR1 mutation; SERENA-6 trial; CDK4/6 inhibitor; disease progression; ASCO 2025; treatment resistance

Merck Advances Middle Dose of ROR1 ADC in Relapsed/Refractory DLBCL After Safety Review

1 week ago talkbio0Tagged Adverse event, Clinical Trials, Diffuse Large B-Cell Lymphoma, Merck, middle dose, Relapsing course, ROR1 protein, human, Safety, therapeutic autologous dendritic cells, Unresponsive to Treatment, vedotin, waveLINE-003, Zilovertamab

Merck; ROR1; ADC; zilovertamab vedotin; middle dose; 1.75 mg/kg; relapsed DLBCL; refractory DLBCL; WaveLINE-003; safety; adverse events; clinical trial; ASCO 2025

Analysts Downplay Intellia Adverse Event, but Gene Therapy Safety Remains Under Scrutiny

1 week ago talkbio0Tagged Adverse event, ATTR-CM, Event, Gene Modification, gene therapy, Intellia, liver transaminase, MAGNITUDE trial, Response process, Safety, Stock Decline

Intellia Therapeutics; gene therapy; safety event; adverse event; MAGNITUDE trial; liver transaminase; stock decline; ATTR-CM; gene editing; analyst response

Patient Death in Rocket Pharmaceuticals Gene Therapy Trial Prompts FDA Clinical Hold

2 weeks ago talkbio0Tagged acute systemic infection, Adverse event, Capillary Leak Syndrome, gene therapy, Glycogen Storage Disease Type IIb, Patient Death, Rocket, RP-A501, Study on Hold, United States Food and Drug Administration

Rocket Pharmaceuticals; gene therapy; Danon disease; clinical hold; FDA; patient death; capillary leak syndrome; acute systemic infection; RP-A501; adverse event

Tourmaline Bio’s Heart Drug Pacibekitug Shows Promise Against Cardiovascular Inflammation, Targets Competition with Novo, CSL

3 weeks ago talkbio0Tagged Cardiovascular system, heart drug, Inflammation, interleukin-6, Markers (device), Nordisk, pacibekitug, Phase 2 trial, SMPX gene, tourmaline, United States Food and Drug Administration

Tourmaline Bio; heart drug; pacibekitug; cardiovascular inflammation; inflammation markers; Novo Nordisk; CSL; Phase 2 trial; FDA; IL-6

FDA, CDC call for pause of chikungunya shot rollout in older adults

4 weeks ago talkbio0Tagged Adverse event, Centers for Disease Control and Prevention (U.S.), Chikungunya Fever, concerns, Elderly (population group), Ixchiq vaccine, pause recommendation, Safety, United States Food and Drug Administration

Ixchiq vaccine, chikungunya, safety concerns, older adults, FDA, CDC, pause recommendation, adverse events

Sanofi axes IGM pact, sparking 80% layoffs at the biotech and facility closures

1 month ago talkbio0Tagged Biosciences, Biotech Layoffs, Collaboration termination, Facility (object), IgM antibodies, Immunoglobulin M, Immunology, Inflammation, Neoplasms, Reparative closure, sanofi

Sanofi, IGM Biosciences, collaboration termination, biotech layoffs, facility closures, IgM antibodies, immunology, inflammation, oncology

Marea Therapeutics Reports Positive Phase 2a Results for MAR001 in Lowering Remnant Cholesterol and Triglycerides

1 month ago1 month ago talkbio0Tagged Adverse event, ANGPTL4 gene, Antibodies, Dosage, Embryonic remnant, Hypertriglyceridemia, MAR001, MAR001[1, Phase 2a clinical trial, placebo-adjusted mean reduction, Positive

MAR001, Antibodies, ANGPTL4 gene, Embryonic remnant, Hypertriglyceridemia, Phase 2a clinical trial, Positive, placebo-adjusted mean reduction, Dosage, Adverse event, MAR001[1

Exact Sciences plans ‘transformative year’ with 3 cancer test debuts

1 month ago talkbio0Tagged Exact brand biomedical or dental material, Hypersensitivity, MRD, Science

Science, MRD, Exact brand biomedical or dental material, Hypersensitivity